Prospective trial of minimal residual disease assessment by multiparametric flow cytometry for multiple myeloma in the era of bortezomib-based chemotherapy. (December 2018) - Clark, C.; Mosse, Claudio; Chen, Heidi; Byrne, Michael; Chinratanalab, Wichai; Engelhardt, Brian; Goodman, Stacey; Harrell, Shelton; Kassim, Adetola; Savani, Bipin; Sengsayadeth, Salyka; Jagasia, Madan; et al.